RGDXQ (Response Genetics) Shares Outstanding (EOP): 13.65 Mil (As of Dec. 2015)


What is Response Genetics Shares Outstanding (EOP)?

Response Genetics RGDXQ -98.00% Shares Outstanding (EOP) is 13.65 Mil as of Dec. 2015.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Response Genetics's shares outstanding for the quarter that ended in Dec. 2015 was 13.65 Mil.

Response Genetics's quarterly shares outstanding declined from Mar. 2015 (38.80 Mil) to Dec. 2015 (13.65 Mil). It means Response Genetics bought back shares from Mar. 2015 to Dec. 2015 .

Response Genetics's annual shares outstanding declined from Dec. 2014 (38.80 Mil) to Dec. 2015 (13.65 Mil). It means Response Genetics bought back shares from Dec. 2014 to Dec. 2015 .


Response Genetics  (OTCPK:RGDXQ) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Response Genetics Shares Outstanding (EOP) Related Terms


Response Genetics Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Response Genetics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics Shares Outstanding (EOP) Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.54 32.80 38.71 38.80 13.65

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.73 38.73 38.80 38.80 13.65

RGDXQ vs PSID, GBSN, ETAH: Shares Outstanding (EOP) Comparison

For the Diagnostics & Research subindustry, Response Genetics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Response Genetics Shares Outstanding (EOP) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Response Genetics's Shares Outstanding (EOP) falls into.



Response Genetics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 13.65 Mil mean?
Response Genetics (RGDXQ) has a Shares Outstanding (EOP) of 13.65 Mil as of Dec. 2015. The total shares a company has outstanding, at period-end. View historical data on Response Genetics and its competitors.
Is Response Genetics' Shares Outstanding (EOP) too high?
Response Genetics' current Shares Outstanding (EOP) is 13.65 Mil.
How does Response Genetics' Shares Outstanding (EOP) compare to PSID and GBSN?
Response Genetics' Shares Outstanding (EOP) of 13.65 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Diagnostics & Research company?
A good Shares Outstanding (EOP) depends on the Medical Diagnostics & Research industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Response Genetics and its competitors. Response Genetics's current Shares Outstanding (EOP) is 13.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Shares Outstanding (EOP) of 13.65 Mil. The current Shares Outstanding (EOP) is 13.65 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Shares Outstanding (EOP) is 13.65 Mil as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.